SPEAKER_00: 0:00

Welcome back to the deep dive. If you're in that high stakes phase of studying, uh, especially for exams like the Pan CE, you know that dermatology isn't just about rashes, it's about life and death differentiations.

SPEAKER_01: 0:12

That's so spot on. The skin and you know its malignancies, they form a fundamental block of knowledge for any aspiring clinician.

SPEAKER_00: 0:21

Right.

SPEAKER_01: 0:21

So while dermatology might only be a small percentage of the test, the difference between correctly identifying a basal cell carcinoma and a thick melanoma, well, that defines patient outcomes.

SPEAKER_00: 0:32

Aaron Powell Okay, so let's unpack this. Our mission today is a real deep dive into the three major skin cancers.

SPEAKER_01: 0:38

Aaron Ross Powell Basal cell carcinoma, squamous cell carcinoma, and malignant melanoma.

SPEAKER_00: 0:43

Aaron Powell Exactly. And we're not just reviewing symptoms, we're framing this whole conversation around clinical practice using those five core task areas you absolutely have to master.

SPEAKER_01: 0:52

History and physical diagnostic studies.

SPEAKER_00: 0:55

Formulating the diagnosis, clinical intervention, and of course health maintenance and prevention.

SPEAKER_01: 0:59

Aaron Powell It's a framework that really helps you move beyond just memorizing facts. It teaches you how to clinically triage a patient from the moment they walk in to, you know, their long-term follow-up.

SPEAKER_00: 1:10

So where do we begin?

SPEAKER_01: 1:11

We begin with the least aggressive, but by far the most common cancer.

SPEAKER_00: 1:16

BCC. And BCC is, epidemiologically speaking, the big winner. It's the most common cancer in the world. And it's typically linked to that intense, intermittent UV exposure. Think of someone who got really bad sunburns as a kid, usually in fair-skinned people.

SPEAKER_01: 1:32

So for your history and physical, you're always asking about that recreational sun exposure and looking very closely at sun exposed areas.

SPEAKER_00: 1:38

Aaron Powell The face, the trunk, lower legs.

SPEAKER_01: 1:41

Exactly. And when you're trying to formulate that diagnosis, the visual cues are uh they're critical. The classic presentation is a papule or a nodule, and sometimes it has a central erosion.

SPEAKER_00: 1:52

Aaron Powell The high yield fact, the one to really lock in, is that pearly or translucent quality.

SPEAKER_01: 1:57

Aaron Powell That is the key. And it's often best seen when you stretch the skin a little. That pearly look combined with those fine, you know, little thread-like blood vessels, the telangia cacias, is highly diagnostic.

SPEAKER_00: 2:08

I think it's so interesting how we have this textbook BCC in our minds, but it can look totally different depending on the subtype.

SPEAKER_01: 2:15

Oh, absolutely. That's a huge clinical caveat. The superficial BCC, for example, it's usually on the back or chest and looks less like a pearly nodule.

SPEAKER_00: 2:24

And more like what?

SPEAKER_01: 2:25

More like a reddish, shiny, scaly, thin plaque. I mean, you could easily mistake it for a bit of eczema or even tiny.

SPEAKER_00: 2:32

And then there's the really tricky one, morphia form.

SPEAKER_01: 2:36

Yes, that one is highly infiltrative and looks, well, deceptively like a pale depressed scar. Very easy to miss if you're not looking for it.

SPEAKER_00: 2:44

And we absolutely have to mention the immunosuppressed population.

SPEAKER_01: 2:47

That is a crucial point. Patients on immunosuppressive therapy think long-term transplant recipients or those with something like non-Hodgkin lymphoma, they're far more likely to get BCC. And when they do get them, the lesions tend to be more aggressive and they recur much more frequently.

SPEAKER_00: 3:03

So once we suspect a BCC from the exam, we need to confeme it. What's the diagnostic path?

SPEAKER_01: 3:09

You need confirmation. So that means a shave or a punch biopsy to determine the exact histology. Once it's confirmed, the clinical intervention is pretty straightforward. Get rid of it.

SPEAKER_00: 3:21

With the highest cure rate and the least tissue loss.

SPEAKER_01: 3:24

Precisely. Standard surgical excision is very effective. You're looking at recurrence rates of 5% or less.

SPEAKER_00: 3:30

But for some spots, 5% is still too high, or you just can't afford to lose the tissue. And that brings us to MoS surgery. This is where it gets really interesting.

SPEAKER_01: 3:39

Mo's is the gold standard. The cure rates approach 98%.

SPEAKER_00: 3:43

And why is it so good?

SPEAKER_01: 3:45

Because the surgeon removes a layer and then immediately processes and views the margins right there in the suite.

SPEAKER_00: 3:51

So you know right away if you got it all.

SPEAKER_01: 3:53

Instantly. If cancer cells are seen, another small layer is taken only from that specific positive margin. It's a layer-by-layer approach that ensures total clearance while sparing the most healthy tissue possible.

SPEAKER_00: 4:04

Which makes perfect sense for those high-risk, cosmetically sensitive areas.

SPEAKER_01: 4:08

Exactly. We save MOS for the eyelids, the external ear, the temple, or for any recurrent lesions or those aggressive subtypes like morphiaform.

SPEAKER_00: 4:18

And what about non-surgical options for those superficial types on the trunk, for instance?

SPEAKER_01: 4:21

Aaron Powell For superficial BCCs, yeah, we can use topical treatments. Imickimod is one, applied five nights a week for six to ten weeks. It basically stimulates a local immune response. Or topical five fluorocyl, which is a chemotherapy agent. Systemic therapy is rare. It's really reserved for advanced or metastatic cases. That's where you'd use something called a hedgehog pathway inhibitor.

SPEAKER_00: 4:43

Just briefly, what is the hedgehog pathway?

SPEAKER_01: 4:46

It's a signaling pathway that um drives cell growth. It's often abernly activated in BCC. So these drugs just block that signal, shutting the cancer down from the inside.

SPEAKER_00: 4:56

Great context. Okay, let's move to health maintenance. BCC patients are famous for getting a second one.

SPEAKER_01: 5:01

Yes, up to half of patients will develop another BCC. So the HMPEP mandate is clear. At least yearly full-body skin exams are required.

SPEAKER_00: 5:09

And for those high-risk patients.

SPEAKER_01: 5:10

For them, remember this high yield fact. Oral nicotinamide, 500 milligrams twice daily, can decrease the rate of new BCC development by about 20%. It's a powerful tool.

SPEAKER_00: 5:23

Okay, let's transition now to squamous cell carcinoma. So if BCC is locally destructive, SEC is where we start talking about real metastatic potential.

SPEAKER_01: 5:32

Aaron Ross Powell Right. And SEC arises from prolonged cumulative sun exposure. It often evolves from precursor lesions like ectinic keratosis.

SPEAKER_00: 5:41

Aaron Powell And the clinical urgency here just ramps up dramatically, especially in those same immunosuppressed groups.

SPEAKER_01: 5:47

It really does. An organ transplant recipient, for instance, can have up to a hundredfold increased risk of developing SEC. And those tumors are inherently more aggressive.

SPEAKER_00: 5:56

Aaron Powell So for history and physical, what are we looking for? How's it different from that pearly BCC?

SPEAKER_01: 6:03

More keratinized. It often presents as a non-healing ulcer or warty firm nodule. You might see an irregular pink plaque with a crust on it, often on the head, neck, or arms.

SPEAKER_00: 6:13

Aaron Powell The texture is a key difference then.

SPEAKER_01: 6:15

Aaron Powell The texture and the tendency to ulcerate early, yes.

SPEAKER_00: 6:18

You mentioned metastatic risk. The overall rate for sun-induced SECs is low, maybe three to seven percent, but some features make us worry immediately.

SPEAKER_01: 6:25

And that's clinical triage. We worry a lot about SECs on high-risk sites because of the lymphatic drainage. Think mucosal surfaces, the lip, the ear, the scalp, the temple.

SPEAKER_00: 6:36

Why those spots specifically?

SPEAKER_01: 6:37

They have significantly higher rates of recurrence and metastasis. It means you need a much more aggressive management plan from day one.

SPEAKER_00: 6:44

So given that risk, is MOSE surgery the preferred treatment for most SECs?

SPEAKER_01: 6:50

It's highly prioritized, I'd say. Excision or MOSE is preferred, but MOSE is specifically recommended for all those high-risk sites, lips, nose, ears, or for any recurrent tumors or large lesions.

SPEAKER_00: 7:02

Aaron Powell And in any of those high-risk immunosuppressed patients.

SPEAKER_01: 7:05

Absolutely. The surgical margins for SEC are also generally larger than for BCC because of that increased risk of subclinical spread.

SPEAKER_00: 7:11

And what if we catch it early, like an SEC in situ?

SPEAKER_01: 7:14

If it's superficial, just in the epidermis, we have similar options to BCC. Topical amicamod, phi fluorocill, or a simple curatage and electrodesiccation.

SPEAKER_00: 7:24

But when SEC becomes advanced or metastatic, that's a whole different ballgame.

SPEAKER_01: 7:30

It is. The treatment shifts to systemic therapies. And the real breakthrough here has been immunotherapy, specifically PD1 blockade.

SPEAKER_00: 7:39

Let's pause there because the way PD1 blockade works is fascinating.

SPEAKER_01: 7:43

It's a complete paradigm shift. Cancer cells can express these proteins like PDL1 that bind to PD1 receptors on your T cells.

SPEAKER_00: 7:51

Which basically tells the immune system to stand down.

SPEAKER_01: 7:53

It puts the brakes on the immune system. Exactly. PD1 blockade therapy just, well, it takes the brakes off. It unleashes the T cells to go recognize and destroy the cancer.

SPEAKER_00: 8:02

Incredible. So for health maintenance with SEC, with a metastatic risk, follow-up has to be different.

SPEAKER_01: 8:09

It absolutely must. Follow-up exams, at least yearly and critically, they must include a careful, thorough palpation of the draining lymph nodes.

SPEAKER_00: 8:17

And just like with BCC, there's a role for nicotinamide.

SPEAKER_01: 8:21

Yes, and here's another great number for your memory bank. Oral nicotinamide can decrease SEC development by an impressive 30% in high-risk groups.

SPEAKER_00: 8:29

30%? Wow. Okay, now we arrive at malignant melanoma. This isn't the most common skin cancer, but it's the leading cause of death from skin disease.

SPEAKER_01: 8:39

It is. And it introduces an immediate, intense anxiety that just isn't there with a BCC diagnosis.

SPEAKER_00: 8:46

And that anxiety is justified.

SPEAKER_01: 8:48

Completely. The history and physical is so critical because early detection is curative. You have to suspect melanoma in any pigmented lesion that has recently changed.

SPEAKER_00: 8:58

So most of them don't come from existing moles, right?

SPEAKER_01: 9:00

That's right. Less than 30%. Most arise de novo. So the single most important historical factor is change evolution, especially new bleeding or ulceration.

SPEAKER_00: 9:09

Aaron Powell We all learn the ABCDE rule in school. How do you use that effectively as a clinician?

SPEAKER_01: 9:14

The ABCDE's asymmetry, border, color, diameter, evolution give you the parameters. But honestly, the most powerful tool is offered the ugly duckling sign.

SPEAKER_00: 9:24

The outlier.

SPEAKER_01: 9:24

The outlier. If one mole looks totally different from all the others on the patient's body, that's the one you biopsy.

SPEAKER_00: 9:30

We should also touch on the subtypes, especially in populations where sun isn't the main cause.

SPEAKER_01: 9:34

Of course. Superficial spreading melanoma is the most common, about two-thirds of cases, and that's the classic UV link type. But acro lentigenous melanoma is key in people with darker skin.

SPEAKER_00: 9:46

And where do those appear?

SPEAKER_01: 9:47

On the palms, soles, and under the nail beds. And unfortunately, diagnosis is often delayed because the nine pigmented lesions are so common in those areas.

SPEAKER_00: 9:57

So once we decide to biopsy, what is the single most important piece of information we get back?

SPEAKER_01: 10:03

Without a doubt, it's melanoma thickness, the breast low depth. It is the single most important prognostic factor. It dictates everything that comes next.

SPEAKER_00: 10:12

And the survival stats really hammer home why early detection is everything.

SPEAKER_01: 10:17

They really do. For thin melanomas less than one millimeter deep, the 10-year survival is excellent, about 95%.

SPEAKER_00: 10:24

But that number drops off a cliff.

SPEAKER_01: 10:25

It does. For lesions that are two to four millimeters thick, the 10-year survival plummets to 55%. That small difference in depth just dramatically changes a patient's life.

SPEAKER_00: 10:35

So after the initial biopsy confirms the depth, what's the next diagnostic step for, say, an intermediate risk patient?

SPEAKER_01: 10:42

For them, sentinel lymph node biopsy is the key staging procedure. It tells us if there's microscopic spread. And for more advanced disease, we also use lab studies to look for genetic mutations.

SPEAKER_00: 10:54

Like BRAF mutations.

SPEAKER_01: 10:56

Exactly. BRAF mutations are crucial because identifying one opens the door to highly effective targeted therapy.

SPEAKER_00: 11:02

Aaron Powell So the main clinical intervention is surgical, but the size of the excision is totally dependent on that Breslow depth.

SPEAKER_01: 11:09

Precisely. We re-excise based on thickness. For melanoma in situ, we only need about half a centimeter to one centimeter margins. For a lesion under one millimeter, we take one centimeter.

SPEAKER_00: 11:20

And for thicker ones.

SPEAKER_01: 11:21

Over one millimeter, the margin increases to one to two centimeters. It's a very precise, thickness-driven intervention.

SPEAKER_00: 11:27

And for patients with spread to the lymph nodes or beyond, it's a referral to an expert center.

SPEAKER_01: 11:32

Yes. And that's where those targeted therapies and immunotherapies, like the PD1 treatments we discussed, become the backbone of management. The conversation shifts from a local surgical problem to a systemic disease.

SPEAKER_00: 11:44

So to wrap up, what's the core health maintenance message for a melanoma patient?

SPEAKER_01: 11:49

It's all about patient education and empowerment. Regular, diligent skin self-exams, and professional annual evaluations are foundational. And you have to educate them on the ABCDEs, but really emphasize change, the E for evolution. That's the most crucial takeaway.

SPEAKER_00: 12:05

So what does this all really mean? We've covered three distinct cancers that represent a kind of triage spectrum.

SPEAKER_01: 12:11

Exactly. BCC is indolent but can be locally recurrent. SCC has a low but very real metastatic risk, especially in certain locations or patients.

SPEAKER_00: 12:21

And MM carries the highest mortality risk, where a few millimeters of depths can be the difference between a 95% and a 55% survival.

SPEAKER_01: 12:29

And that difference in metastatic potential provides your foundational clinical system. It tells you immediately if you need to check the lymph nodes, if you need MOS surgery, and how aggressively you need to follow up with that patient.

SPEAKER_00: 12:40

It really shows the huge clinical difference between the local disease and a systemic one. We saw that for early melanoma, surgery is curative.

SPEAKER_01: 12:47

But once that thickness threshold is crossed, the treatment becomes immunotherapy activating the entire systemic immune system to destroy the cancer.

SPEAKER_00: 12:55

Which leaves us with a final provocative thought for you to consider.

SPEAKER_01: 12:59

How does this fundamental reliance on activating the patient's own complex immune machinery, you know, via PD1 blockade, fundamentally change your conceptual approach to fighting cancer compared to the established model of just simple surgical removal?

SPEAKER_00: 13:14

A fascinating concept to mull over as you continue your studies. Thanks for diving deep with us today and for continuing your journey toward being a well informed clinician.